

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

NALOX-1 PHARMACEUTICALS, LLC,  
Petitioner,

v.

ADAPT PHARMA OPERATIONS LIMITED, and  
OPIANT PHARMACEUTICALS, INC.,  
Patent Owners.

---

Case IPR2019-00688  
U.S. Patent 9,468,747

---

**PATENT OWNERS' REQUEST FOR ORAL ARGUMENT**

Pursuant to 37 C.F.R. § 42.70 and DUE DATE 4 of the Board's Scheduling Order (Paper 12), Patent Owners Adapt Pharma Operations Limited and Opiant Pharmaceuticals, Inc. respectfully request oral argument, currently scheduled for May 19, 2020. Patent Owners specify, without intent to waive consideration of any issue not listed below, the following issues for argument:

1. Patentability of the challenged claims, including but not limited to all issues raised the Petition, Patent Owners' Preliminary Response, Patent Owners' Response, Petitioner's Reply to Patent Owners' Response, and Patent Owners Sur-reply (to be filed); the declarations of Dr. Maureen Donovan, Dr. Günther Hochhaus, Dr. Kenneth Williams, Dr. Stuart Jones, Dr. Robert Vigil, Thomas Begres, Declan Brides, and Eric Karas; as well as all other exhibits filed in this proceeding; and
2. Any motions or observations filed in this proceeding.

### **REQUESTED ARGUMENT DURATION**

Patent Owners have met and conferred with Petitioner Nalox-1 Pharmaceuticals, LLC, and the parties agree that the oral arguments in IPR2019-00685, IPR2019-00688, and IPR2019-00694 should be consolidated. The parties further agree that each side should be given forty-five (45) minutes to present their respective arguments in the foregoing cases, for a total of ninety (90) minutes.

## EQUIPMENT REQUEST & VENUE

Patent Owners request audio/visual equipment to display demonstrative exhibits, including equipment necessary to allow the exhibits to be viewed by any Judge participating remotely. Patent Owners further acknowledge that according to the Board's scheduling order, oral argument will be held at the U.S. Patent and Trademark Office headquarters in Alexandria, Virginia. Patent Owners do not request a different venue. While Patent Owners would prefer an in-person argument, in light of the ongoing COVID-19 pandemic, should the parties be unable to present oral argument in person, Patent Owners request that oral argument be conducted by videoconference.

Dated: April 6, 2020

Respectfully submitted,

/Jessamyn S. Berniker/

Jessamyn S. Berniker (Reg. No. 72,328)

Ana C. Reyes (Admitted *Pro Hac Vice*)

David M. Krinsky (Reg. No. 72,339)

Anthony H. Sheh (Reg. No. 70,576)

WILLIAMS & CONNOLLY LLP

725 Twelfth Street, N.W.

Washington, DC 20005

jberniker@wc.com

areyes@wc.com

dkrinsky@wc.com

asheh@wc.com

EmergentNarcant@wc.com

*Counsel for Patent Owner*

*Adapt Pharma Operations Ltd.*

Case IPR2019-00688  
U.S. Patent 9,468,747

Jessica Tyrus Mackay (Reg. No. 64,742)  
Ann K. Kotze (Reg. No. 76,570)  
GREEN, GRIFFITH & BORG-BREEN, LLP  
676 North Michigan Avenue  
Suite 3900  
Chicago, IL 60611  
jmackay@greengriffith.com  
akotze@greengriffith.com

*Counsel for Patent Owner  
Opiant Pharmaceuticals, Inc.*

**CERTIFICATE OF SERVICE**

Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certifies that a true and correct copy of the foregoing was served on April 6, 2020 by delivering a copy via electronic mail on the following attorneys of record:

Yelee Y. Kim  
Janine A. Carlan  
Richard Berman  
Bradford Frese  
Christopher Yaen  
ARENT FOX LLP  
1717 K Street NW  
Washington, DC 20006  
Yelee.Kim@arentfox.com  
Janine.Carlan@arentfox.com  
Richard.Berman@arentfox.com  
Bradford.Frese@arentfox.com  
Christopher.Yaen@arentfox.com

*/Jessamyn S. Berniker/*  
\_\_\_\_\_  
Jessamyn S. Berniker